Suppr超能文献

长链非编码RNA PCAT6通过调控miR-139-3p/BRD4轴来调节垂体腺瘤的进展。

LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis.

作者信息

Zhao Peng, Cheng Jianhua, Li Bin, Nie Ding, Wang Hongyun, Li Chuzhong, Gui Songbai, Zhang Yazhuo

机构信息

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China.

Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.

出版信息

Cancer Cell Int. 2021 Jan 6;21(1):14. doi: 10.1186/s12935-020-01698-7.

Abstract

BACKGROUND

Dysregulated lncRNA PCAT6 was discovered in many cancers excluding pituitary adenomas (PA). Therefore, we explored the role of PCAT6 in PA in this research.

METHODS

Abnormally expressed miRNAs were analyzed by bioinformatics and RT-qPCR. The target and regulator of miR-139-3p were determined by bioinformatics, dual-luciferase reporter assay, or RIP. The correlation among PCAT6, miR-139-3p, and BRD4 was further analyzed. The viability, apoptosis, cell cycle distribution of PA cells, as well as their ability to invade, migrate, and proliferate, were tested after transfection through CCK-8, flow cytometry, transwell, wound healing, and colony formation assays. After construction of transplanted-tumor model in nude mice, cell apoptosis in the tumor was detected by TUNEL. The expressions of PCAT6, BRD4, miR-139-3p, and apoptosis-related factors in PA tissues, cells, or tumor tissues were detected by RT-qPCR, Western blot, or IHC.

RESULTS

PCAT6 and BRD4 were high-expressed but miR-139-3p was low-expressed in PA. Both the 3'-untranslated regions of PCAT6 and BRD4 mRNAs were demonstrated to contain a potential binding site for miR-139-3p. PCAT6 was positively correlated to BRD4, and miR-139-3p was negatively correlated to PCAT6 and BRD4. MiR-139-3p mimic, shPCAT6 and siBRD4 inhibited the viability, migration, invasion, and proliferation of PA cells while inducing apoptosis. MiR-139-3p mimic and shPCAT6 inhibited the cell cycle progression of PA cells, decreased the weight and volume of the xenotransplanted tumor, and reduced the levels of Bcl-2 and BRD4 while enhancing the levels of Bax, miR-139-3p, and Cleaved caspase-3. MiR-139-3p inhibitor caused the opposite effect of miR-139-3p mimic and further reversed the effect of shPCAT6 on on PA cells.

CONCLUSION

PCAT6 regulated the progression of PA via modulating the miR-139-3p/BRD4 axis, which might provide a novel biomarker for the prevention, diagnosis, and treatment of PA.

摘要

背景

失调的长链非编码RNA PCAT6在除垂体腺瘤(PA)外的许多癌症中被发现。因此,我们在本研究中探讨了PCAT6在PA中的作用。

方法

通过生物信息学和逆转录-定量聚合酶链反应(RT-qPCR)分析异常表达的微小RNA(miRNA)。通过生物信息学、双荧光素酶报告基因检测或RNA免疫沉淀(RIP)确定miR-139-3p的靶标和调节因子。进一步分析PCAT6、miR-139-3p和溴结构域蛋白4(BRD4)之间的相关性。转染后,通过细胞计数试剂盒-8(CCK-8)、流式细胞术、Transwell小室、伤口愈合和集落形成试验检测PA细胞的活力、凋亡、细胞周期分布以及侵袭、迁移和增殖能力。在裸鼠中构建移植瘤模型后,通过TUNEL法检测肿瘤中的细胞凋亡。通过RT-qPCR、蛋白质免疫印迹法(Western blot)或免疫组化(IHC)检测PA组织、细胞或肿瘤组织中PCAT6、BRD4、miR-139-3p和凋亡相关因子的表达。

结果

PCAT6和BRD4在PA中高表达,但miR-139-3p低表达。PCAT6和BRD4 mRNA的3'-非翻译区均被证明含有miR-139-3p的潜在结合位点。PCAT6与BRD4呈正相关,miR-139-3p与PCAT6和BRD4呈负相关。miR-139-3p模拟物、短发夹RNA(shPCAT6)和小干扰RNA(siBRD4)抑制PA细胞的活力、迁移、侵袭和增殖,同时诱导凋亡。miR-139-3p模拟物和shPCAT6抑制PA细胞的细胞周期进程,降低异种移植瘤的重量和体积,降低B细胞淋巴瘤-2(Bcl-2)和BRD4的水平,同时提高Bax、miR-139-3p和裂解的半胱天冬酶-3(Cleaved caspase-3)的水平。miR-139-3p抑制剂产生与miR-139-3p模拟物相反的作用,并进一步逆转shPCAT6对PA细胞的作用。

结论

PCAT6通过调节miR-139-3p/BRD4轴调控PA的进展,这可能为PA的预防、诊断和治疗提供一种新的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/782c/7789787/585020959b34/12935_2020_1698_Fig1_HTML.jpg

相似文献

1
LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis.
Cancer Cell Int. 2021 Jan 6;21(1):14. doi: 10.1186/s12935-020-01698-7.
3
Long non-coding RNA PCAT6 regulates bladder cancer progression via the microRNA-143-3p/PDIA6 axis.
Exp Ther Med. 2021 Sep;22(3):947. doi: 10.3892/etm.2021.10379. Epub 2021 Jul 1.
4
LncRNA PCAT6 mediates UBFD1 expression via sponging miR-545-3p in breast cancer cells.
Noncoding RNA Res. 2024 Feb 8;9(2):421-428. doi: 10.1016/j.ncrna.2024.01.019. eCollection 2024 Jun.
5
LncRNA PCAT6 Accelerates the Progression and Chemoresistance of Cervical Cancer Through Up-Regulating ZEB1 by Sponging miR-543.
Onco Targets Ther. 2020 Feb 7;13:1159-1170. doi: 10.2147/OTT.S232354. eCollection 2020.
8
lncRNA PCAT6 promotes non-small cell lung cancer cell proliferation, migration and invasion through regulating miR-330-5p.
Onco Targets Ther. 2018 Nov 1;11:7715-7724. doi: 10.2147/OTT.S178597. eCollection 2018.

引用本文的文献

1
Exosomal AFAP1-AS1 Promotes the Growth, Metastasis, and Glycolysis of Pituitary Adenoma by Inhibiting HuR Degradation.
Mol Neurobiol. 2025 Feb;62(2):2212-2229. doi: 10.1007/s12035-024-04387-y. Epub 2024 Aug 2.
2
The interplay between microRNAs and Nrf2 signaling in human cancers.
Cancer Cell Int. 2024 Jul 5;24(1):234. doi: 10.1186/s12935-024-03430-1.
3
Interplay between lncRNA/miRNA and Wnt/ß-catenin signaling in brain cancer tumorigenesis.
EXCLI J. 2023 Nov 28;22:1211-1222. doi: 10.17179/excli2023-6490. eCollection 2023.
5
Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma.
Cells. 2022 Sep 19;11(18):2920. doi: 10.3390/cells11182920.
6
, an Emerging Gate-Keeper in Various Types of Cancer.
Cells. 2022 Feb 22;11(5):769. doi: 10.3390/cells11050769.
7
MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells.
Mol Biotechnol. 2022 Jul;64(7):832-840. doi: 10.1007/s12033-022-00462-8. Epub 2022 Feb 12.
8
miR-124a Involves in the Regulation of Wnt/-Catenin and P53 Pathways to Inhibit Abdominal Aortic Aneurysm via Targeting BRD4.
Comput Math Methods Med. 2022 Jan 21;2022:9241959. doi: 10.1155/2022/9241959. eCollection 2022.
9
May Be a Whistler and Checkpoint Target for Precision Therapy in Human Cancers.
Cancers (Basel). 2021 Dec 3;13(23):6101. doi: 10.3390/cancers13236101.
10
The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.
Cancers (Basel). 2021 Nov 28;13(23):5987. doi: 10.3390/cancers13235987.

本文引用的文献

1
Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade.
Cancer Cell Int. 2020 Aug 8;20:383. doi: 10.1186/s12935-020-01475-6. eCollection 2020.
2
ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Genome Med. 2020 Jul 15;12(1):63. doi: 10.1186/s13073-020-00760-3.
5
Pituitary Adenomas with Changing Phenotype: A Systematic Review.
Exp Clin Endocrinol Diabetes. 2020 Dec;128(12):835-844. doi: 10.1055/a-1120-8277. Epub 2020 Apr 14.
6
Expression analysis of vimentin and the related lncRNA network in breast cancer.
Exp Mol Pathol. 2020 Aug;115:104439. doi: 10.1016/j.yexmp.2020.104439. Epub 2020 Apr 10.
8
Clinical study of endoscopic treatment of a sellar pituitary adenomas with sellar diaphragm defect.
BMC Neurol. 2020 Apr 11;20(1):129. doi: 10.1186/s12883-020-01690-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验